bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
Given the dependence of modern medicine on antimicrobial drugs, and the inevitability of evolution, why is bringing a new antibiotic to market so difficult, and why are so many companies leaving the industry or going bankrupt?
Antimicrobial resistance (AMR) presents a global health crisis, as every day we encounter more infections that cannot be cured with existing antimicrobials. At the same time, the majority of major drug companies have been scaling back or cutting antibiotic research due to development challenges
Significant action from national and international leadership is needed to encourage and require antimicrobial stewardship programs in healthcare organizations.
About 80 percent of all antibiotics used in the U.S. are used in the animal health and agriculture sectors. This portion contributes significantly to antimicrobial resistance (AMR), as antibiotic dosing regimens tend to be less controlled in agriculture compared to human medicine. AMR is one of our world’s most pressing healthcare challenges and the misuse of antibiotics causes AMR to occur more rapidly.
It is estimated that one out of every twenty hospitalized...
As COVID-19 continues to spread, misinformation has often been more...